Clinical Trial

Prostate Cancer Patient Management With 18F-DCFPyL PET/CT

Enrolling by Invitation Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a multi-center, single-arm, open-label, phase III trial in patients with biopsy-proven prostate cancer. Patients will receive regular standard of clinical care. The only study-specific procedures will the administration of 18F-DCFPyL followed by a PET/CT scan. Differences in theoretical optimal clinical management based on a review of clinical, biochemical and radiographic subject data before and after 18F-DCFPyL PET/CT imaging by a central panel of experts will be captured at study completion.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2018-03-08; most recent amendment 2023-11-22.
Status change: Not Yet Recruiting → Enrolling by Invitation 2018-08-07
Trial Details
NCT Number NCT03459820
Lead Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Conditions Prostate Cancer
Enrollment 1,500 participants
Start Date 2018-06-22
Primary Completion 2027-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2023-11-27